chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 53.0
Sex: U
Vaccine: COVID19
Symptoms: Expired product administered, No adverse event
Clinical narrative: No adverse event; Dose administered after manufacturer date of expiry; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Dose administered after manufacturer date of expiry) and NO ADVERSE EVENT (No adverse event) in a 53-year-old patient of an unknown gender who received mRNA-1273 (Spikevax) (batch no. 038A22A) for COVID-19 prophylaxis.     No Medical History information was reported.    On 24-Feb-2023, the patient received first dose of mRNA-1273 (Spikevax) (unknown route) .5 milliliter. On 24-Feb-2023, the patient experienced EXPIRED PRODUCT ADMINISTERED (Dose administered after manufacturer date of expiry). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Dose administered after manufacturer date of expiry) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 (Spikevax) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (Dose administered after manufacturer date of expiry).    Concomitant medications were not reported.  Patient received the vaccine at 12:28 pm.  It was unknown if patient received any other vaccines in the 4 weeks prior to COVID-19 vaccine.   The vaccine had been frozen with no known temperature excursion before being thawed for administration.  Date the vial was initially stored in the refrigerator was 24-Feb-2023.  The vial did not undergone any temperature excursions.  Treatment information was not reported.   This case was linked to US-MODERNATX, INC.-MOD-2023-712705, US-MODERNATX, INC.-MOD-2023-712700 (E2B Linked Report).   Most recent FOLLOW-UP information incorporated above includes: On 24-Feb-2023: Live follow up contains the administration time of suspect product.; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-712705: US-MODERNATX, INC.-MOD-2023-712698:
Age: 59.0
Sex: F
Vaccine: COVID19-2
Symptoms: Expired product administered, No adverse event, Product storage error
Clinical narrative: Patient was administered Bivalent vaccine which was 2 days beyond the 30 day; No adverse event; Patient was inadvertently administered the bivalent vaccine which was 2 days beyond the 30 day to a patient on 20Feb2023; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Patient was inadvertently administered the bivalent vaccine which was 2 days beyond the 30 day  to a patient on 20Feb2023), PRODUCT STORAGE ERROR (Patient was administered Bivalent vaccine which was 2 days beyond the 30 day) and NO ADVERSE EVENT (No adverse event) in a 59-year-old female patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 041H22A) for COVID-19 prophylaxis.     Previously administered products included for COVID-19 prophylaxis: Moderna COVID-19 Vaccine (1st dose , Lot number: 033C22A) on 01-Jun-2021, Moderna COVID-19 Vaccine (2nd dose , Lot number: 047C21A) on 29-Jun-2021, Moderna COVID-19 Vaccine (1st booster dose , Lot number: 033H21A) on 10-Jan-2022, Moderna COVID-19 Vaccine (2nd booster dose  and Lot number: 016B22A) on 09-Aug-2022. Past adverse reactions to the above products included No adverse event with Moderna COVID-19 Vaccine, Moderna COVID-19 Vaccine, Moderna COVID-19 Vaccine and Moderna COVID-19 Vaccine.    On 20-Feb-2023, the patient received fifth dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 20-Feb-2023,  after starting mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)), the patient experienced EXPIRED PRODUCT ADMINISTERED (Patient was inadvertently administered the bivalent vaccine which was 2 days beyond the 30 day to a patient on 20Feb2023). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (Patient was administered Bivalent vaccine which was 2 days beyond the 30 day) and NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Patient was inadvertently administered the bivalent vaccine which was 2 days beyond the 30 day to a patient on 20Feb2023), PRODUCT STORAGE ERROR (Patient was administered Bivalent vaccine which was 2 days beyond the 30 day) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for EXPIRED PRODUCT ADMINISTERED (Patient was inadvertently administered the bivalent vaccine which was 2 days beyond the 30 day to a patient on 20Feb2023) and PRODUCT STORAGE ERROR (Patient was administered Bivalent vaccine which was 2 days beyond the 30 day).    Patient medical history information included high cholesterol.  No concomitant medications were reported.  No treatment information was provided.
Age: 64.0
Sex: M
Vaccine: COVID19-2
Symptoms: Circumstance or information capable of leading to medication error, No adverse event
Clinical narrative: Nurse is calling to report that a 64 -year-old patient received 5 doses of Moderna COVID-19 vaccine. The last dose was administered on 10SEP2022; No adverse event; This spontaneous case was reported by an other health care professional and describes the occurrence of CIRCUMSTANCE OR INFORMATION CAPABLE OF LEADING TO MEDICATION ERROR (Nurse is calling to report that a 64 -year-old patient received 5 doses of Moderna COVID-19 vaccine. The last dose was administered on 10SEP2022) and NO ADVERSE EVENT (No adverse event) in a 64-year-old male patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. AS7145B) for COVID-19 prophylaxis.     No Medical History information was reported.    On 10-Sep-2022, the patient received fifth dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On an unknown date, the patient experienced CIRCUMSTANCE OR INFORMATION CAPABLE OF LEADING TO MEDICATION ERROR (Nurse is calling to report that a 64 -year-old patient received 5 doses of Moderna COVID-19 vaccine. The last dose was administered on 10SEP2022) and NO ADVERSE EVENT (No adverse event). At the time of the report, CIRCUMSTANCE OR INFORMATION CAPABLE OF LEADING TO MEDICATION ERROR (Nurse is calling to report that a 64 -year-old patient received 5 doses of Moderna COVID-19 vaccine. The last dose was administered on 10SEP2022) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for CIRCUMSTANCE OR INFORMATION CAPABLE OF LEADING TO MEDICATION ERROR (Nurse is calling to report that a 64 -year-old patient received 5 doses of Moderna COVID-19 vaccine. The last dose was administered on 10SEP2022).    No concomitant medications were reported. Reporter stated that she can not be sure if the lot number AS7145B is a Bivalent or Monovalent Moderna COVID-19 vaccine. No treatment medications were reported.
Sex: U
Vaccine: COVID19, COVID19
Symptoms: Expired product administered, No adverse event, Product storage error
Clinical narrative: Moderna Monovalent vaccine was administered to 3 adult patients after after manufacturer date of expiry; No adverse event; Moderna Monovalent vaccine was administered to 3 adult patients after after manufacturer date of expiry; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Moderna Monovalent vaccine was administered to 3 adult patients after after manufacturer date of expiry), PRODUCT STORAGE ERROR (Moderna Monovalent vaccine was administered to 3 adult patients after after manufacturer date of expiry) and NO ADVERSE EVENT (No adverse event) in an adult patient of an unknown gender who received mRNA-1273 (Spikevax) (batch no. 015B22A) for COVID-19 prophylaxis.     No Medical History information was reported.  On 24-Feb-2023, the patient received dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On 24-Feb-2023,  after starting mRNA-1273 (Spikevax), the patient experienced EXPIRED PRODUCT ADMINISTERED (Moderna Monovalent vaccine was administered to 3 adult patients after after manufacturer date of expiry). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (Moderna Monovalent vaccine was administered to 3 adult patients after after manufacturer date of expiry) and NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Moderna Monovalent vaccine was administered to 3 adult patients after after manufacturer date of expiry), PRODUCT STORAGE ERROR (Moderna Monovalent vaccine was administered to 3 adult patients after after manufacturer date of expiry) and NO ADVERSE EVENT (No adverse event) outcome was unknown.     For mRNA-1273 (Spikevax) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for EXPIRED PRODUCT ADMINISTERED (Moderna Monovalent vaccine was administered to 3 adult patients after after manufacturer date of expiry) and PRODUCT STORAGE ERROR (Moderna Monovalent vaccine was administered to 3 adult patients after after manufacturer date of expiry).    No concomitant medications were reported.  The vial was initially stored in the refrigerator on 23-Feb-2023.  It was unknown if the patient received any other vaccines in the 4 weeks prior to COVID-19.  The vial did not undergo any temperature excursions.  No treatment medications were reported.   This case was linked to US-MODERNATX, INC.-MOD-2023-712769, US-MODERNATX, INC.-MOD-2023-712775 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-712769:Patient 2 US-MODERNATX, INC.-MOD-2023-712775:Patient 3
Sex: U
Vaccine: COVID19, COVID19
Symptoms: Expired product administered, No adverse event, Product storage error
Clinical narrative: Moderna Monovalent vaccine was administered to 3 adult patients after after manufacturer date of expiry of 12Feb2023/Date(s) of administration of vaccine 24Feb2023; The vial was initially stored in the refrigerator on 23Feb2023; No adverse event; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Moderna Monovalent vaccine was administered to 3 adult patients after after manufacturer date of expiry of 12Feb2023/Date(s) of administration of vaccine 24Feb2023), PRODUCT STORAGE ERROR (The vial was initially stored in the refrigerator on 23Feb2023) and NO ADVERSE EVENT (No adverse event) in an adult patient of an unknown gender who received mRNA-1273 (Spikevax) (batch no. 015B22A) for COVID-19 prophylaxis.     It was unknown if the patient received any other vaccines in the 4 weeks prior to COVID-19.     On 24-Feb-2023, the patient received dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On an unknown date, the patient experienced EXPIRED PRODUCT ADMINISTERED (Moderna Monovalent vaccine was administered to 3 adult patients after after manufacturer date of expiry of 12Feb2023/Date(s) of administration of vaccine 24Feb2023), PRODUCT STORAGE ERROR (The vial was initially stored in the refrigerator on 23Feb2023) and NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Moderna Monovalent vaccine was administered to 3 adult patients after after manufacturer date of expiry of 12Feb2023/Date(s) of administration of vaccine 24Feb2023), PRODUCT STORAGE ERROR (The vial was initially stored in the refrigerator on 23Feb2023) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 (Spikevax) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for EXPIRED PRODUCT ADMINISTERED (Moderna Monovalent vaccine was administered to 3 adult patients after after manufacturer date of expiry of 12Feb2023/Date(s) of administration of vaccine 24Feb2023) and PRODUCT STORAGE ERROR (The vial was initially stored in the refrigerator on 23Feb2023).    No concomitant medications were reported. Pharmacist reporting Moderna Monovalent vaccine was administered to 3 adult patients after manufacturer date of expiry of 12Feb2023. Consent for Safety Follow up Provided via email. No patient information available at this time. Dose administered after 30-day Use by Date or after manufacturer date of expiry. Individual vial was used, and Vial size was reported ad 5.5 mL. On 23Feb2023 the vial was initially stored in the refrigerator. The vial did not undergo temperature excursions.   No treatment medications were reported.  This case contains information for the 3rd of 3 adult patients described by the reporter.   This case was linked to US-MODERNATX, INC.-MOD-2023-712769, US-MODERNATX, INC.-MOD-2023-712767 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-712769:Patient 2 US-MODERNATX, INC.-MOD-2023-712767:Mater case
Age: 45.0
Sex: F
Vaccine: COVID19-2
Symptoms: Expired product administered, No adverse event, Product storage error
Clinical narrative: This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Dose was administered after more than 12 hours post first vial puncture.), PRODUCT STORAGE ERROR (Initially stored on 20-Feb-2023, First punctured on 21-Feb-2023 and administered on 24-Feb-2023) and NO ADVERSE EVENT (No adverse reactions have been reported by any patients at this time.) in a 45-year-old female patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 022H22A) for COVID-19 prophylaxis. No Medical History information was reported. On 24-Feb-2023, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 24-Feb-2023, after starting mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)), the patient experienced EXPIRED PRODUCT ADMINISTERED (Dose was administered after more than 12 hours post first vial puncture.). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (Initially stored on 20-Feb-2023, First punctured on 21-Feb-2023 and administered on 24-Feb-2023) and NO ADVERSE EVENT (No adverse reactions have been reported by any patients at this time.). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Dose was administered after more than 12 hours post first vial puncture.), PRODUCT STORAGE ERROR (Initially stored on 20-Feb-2023, First punctured on 21-Feb-2023 and administered on 24-Feb-2023) and NO ADVERSE EVENT (No adverse reactions have been reported by any patients at this time.) outcome was unknown.   For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse reactions have been reported by any patients at this time.) to be not related. No further causality assessments were provided for EXPIRED PRODUCT ADMINISTERED (Dose was administered after more than 12 hours post first vial puncture.) and PRODUCT STORAGE ERROR (Initially stored on 20-Feb-2023, First punctured on 21-Feb-2023 and administered on 24-Feb-2023). The concomitant medication was not reported. The date of last administration was 24-Feb-2023. The treatment medication was not reported. The dose was administered more than 12 hours post puncture. The information about individual vial used was unknown. The vial was initially stored in the refrigerator on 20-Feb-2023, first punctured on 21-Feb-2023 at 06:00 am.  Administered on 24-Feb-2023 at 07:45 am and 8.45 am respectively. Most recent FOLLOW-UP information incorporated above includes on 24-Feb-2023: Follow up received included non-significant information reporter's details were updated.
Age: 21.0
Sex: F
Vaccine: COVID19-2
Symptoms: No adverse event, Wrong product administered
Clinical narrative: No adverse event; patient received the 1st dose of the primary series on 29Nov2021 and accidentally she received one dose of Moderna COVID-19 Vaccine Bivalent booster instead of the 2nd dose of the primary series on 15Dec2022; This spontaneous case was reported by a pharmacist and describes the occurrence of WRONG PRODUCT ADMINISTERED (patient received the 1st dose of the primary series on 29Nov2021 and accidentally she received one dose of Moderna COVID-19 Vaccine Bivalent booster instead of the 2nd dose of the primary series on 15Dec2022) and NO ADVERSE EVENT (No adverse event) in a 21-year-old female patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. AS7162B) for COVID-19 prophylaxis.     Previously administered products included for Product used for unknown indication: COVID-19 VACCINE (1st dose of the primary series and lot number: 939903) on 29-Nov-2021. Past adverse reactions to the above products included No adverse event with COVID-19 VACCINE.    On 15-Dec-2022, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 15-Dec-2022,  after starting mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)), the patient experienced WRONG PRODUCT ADMINISTERED (patient received the 1st dose of the primary series on 29Nov2021 and accidentally she received one dose of Moderna COVID-19 Vaccine Bivalent booster instead of the 2nd dose of the primary series on 15Dec2022). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, WRONG PRODUCT ADMINISTERED (patient received the 1st dose of the primary series on 29Nov2021 and accidentally she received one dose of Moderna COVID-19 Vaccine Bivalent booster instead of the 2nd dose of the primary series on 15Dec2022) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for WRONG PRODUCT ADMINISTERED (patient received the 1st dose of the primary series on 29Nov2021 and accidentally she received one dose of Moderna COVID-19 Vaccine Bivalent booster instead of the 2nd dose of the primary series on 15Dec2022).    Concomitant medications details were not reported by the reporter. Patient received the 1st dose of the primary series on 29-Nov-2021 and accidentally she received one dose of Moderna COVID-19 Vaccine Bivalent booster instead of the 2nd dose of the primary series on  15-Dec-2022. Treatment details was not reported by the reporter.
Age: 46.0
Sex: U
Vaccine: COVID19-2
Symptoms: Expired product administered, No adverse event
Clinical narrative: no adverse event; in advertanly gave a moderna bivalent vaccine 4 days after 30 day window; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (in advertanly gave a moderna bivalent vaccine 4 days after 30 day window) and NO ADVERSE EVENT (no adverse event) in a 46-year-old patient of an unknown gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. AS7171B) for COVID-19 prophylaxis.     No Medical History information was reported.    On 14-Feb-2023, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 14-Feb-2023,  after starting mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)), the patient experienced EXPIRED PRODUCT ADMINISTERED (in advertanly gave a moderna bivalent vaccine 4 days after 30 day window). On an unknown date, the patient experienced NO ADVERSE EVENT (no adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (in advertanly gave a moderna bivalent vaccine 4 days after 30 day window) and NO ADVERSE EVENT (no adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (no adverse event) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (in advertanly gave a moderna bivalent vaccine 4 days after 30 day window).    No concomitant medications was provided. No treatment medications was provided.
Age: 35.0
Sex: U
Vaccine: COVID19
Symptoms: Expired product administered, No adverse event
Clinical narrative: This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (7 doses of Moderna monovalent lot number 038A22A, expiration date 10.30.2022, was administered to patients/ Date(s) of administration of vaccine: 24Feb2023) and NO ADVERSE EVENT (No adverse event) in a 35-year-old patient of an unknown gender who received mRNA-1273 (Spikevax) (batch no. 038A22A) for COVID-19 prophylaxis.     No Medical History information was reported.       For mRNA-1273 (Spikevax) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (7 doses of Moderna monovalent lot number 038A22A, expiration date 10.30.2022, was administered to patients/ Date(s) of administration of vaccine: 24Feb2023).    Concomitant medication was not reported.     T
Sex: F
Vaccine: COVID19-2
Symptoms: Limb discomfort, Stress, Vaccination site movement impairment, Vaccination site pain, Vaccination site pruritus
Clinical narrative: This spontaneous case was reported by an other health care professional and describes the occurrence of VACCINATION SITE MOVEMENT IMPAIRMENT (moving it is very difficult/ When she changes her clothes her left arm doesn't work well), LIMB DISCOMFORT (Her arm also felt heavy upon returning home/It feels heavy), STRESS (very stressed), VACCINATION SITE PRURITUS (after receiving the vaccine she started to experience itching on her left arm) and VACCINATION SITE PAIN (she has pain in her left arm) in an adult female patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 016H22A) for COVID-19 prophylaxis.     No other vaccines in the 4 weeks prior to COVID-19 vaccine.  Concurrent medical conditions included Food allergy.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter did not provide any causality assessments.   Contact has received 2 primary vaccine doses on 27SEP2021 (lot number 062E21A) and 25OCT2021 (lot number 040021A). She received a booster dose on 9NOV2022 (lot number 016H22A). While she was waiting for 15 minutes after receiving the vaccine, she started to experience itching on her left arm. She went home and continued to feel itching. She took 10 mg of Hydroxyzine, which she sometimes takes for food allergies and her itching went away 1 hour after that. Her arm also felt heavy upon returning home. She had been using a heat pad and ice pack on her arm.
Age: 43.0
Sex: U
Vaccine: COVID19
Symptoms: Expired product administered, No adverse event
Clinical narrative: No adverse event; Dose of Moderna monovalent lot number 038A22A, expiration date 30-Oct-2022 was administered to patient; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Dose of Moderna monovalent lot number 038A22A, expiration date 30-Oct-2022 was administered to patient) and NO ADVERSE EVENT (No adverse event) in a 43-year-old patient of an unknown gender who received mRNA-1273 (Spikevax) (batch no. 038A22A) for COVID-19 prophylaxis.     No Medical History information was reported.    On 24-Feb-2023 at 1:07 PM, the patient received first dose of mRNA-1273 (Spikevax) (Intramuscular) .5 milliliter. On 24-Feb-2023,  after starting mRNA-1273 (Spikevax), the patient experienced EXPIRED PRODUCT ADMINISTERED (Dose of Moderna monovalent lot number 038A22A, expiration date 30-Oct-2022 was administered to patient). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Dose of Moderna monovalent lot number 038A22A, expiration date 30-Oct-2022 was administered to patient) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 (Spikevax) (Intramuscular), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (Dose of Moderna monovalent lot number 038A22A, expiration date 30-Oct-2022 was administered to patient).    It was unknown if patient received any other vaccines in the 4 weeks prior to COVID-19 vaccine. No concomitant medications was reported.  The vaccine was frozen with no known temperature excursion before being thawed for administration. The vial was initially stored in the refrigerator on 24-Feb-2023. The vial had not undergone any temperature excursions.  No treatment medications was reported.   This case was linked to US-MODERNATX, INC.-MOD-2023-712705, US-MODERNATX, INC.-MOD-2023-712698 (E2B Linked Report).   Most recent FOLLOW-UP information incorporated above includes: On 24-Feb-2023: Follow-up received included no new information.; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-712705: US-MODERNATX, INC.-MOD-2023-712698:
Sex: U
Vaccine: COVID19
Symptoms: Expired product administered, No adverse event
Clinical narrative: no adverse event; My vaccine box did not have a expiry date. When we try to enter it says the expiration was around 14 days back .; This spontaneous case was reported by a physician and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (My vaccine box did not have a expiry date. When we try to enter it says the expiration was around 14 days back .) and NO ADVERSE EVENT (no adverse event) in a child patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. AR9236B) for COVID-19 prophylaxis.     No Medical History information was reported.    On 24-Feb-2023, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. On 24-Feb-2023,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced EXPIRED PRODUCT ADMINISTERED (My vaccine box did not have a expiry date. When we try to enter it says the expiration was around 14 days back .). On an unknown date, the patient experienced NO ADVERSE EVENT (no adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (My vaccine box did not have a expiry date. When we try to enter it says the expiration was around 14 days back .) and NO ADVERSE EVENT (no adverse event) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered NO ADVERSE EVENT (no adverse event) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (My vaccine box did not have a expiry date. When we try to enter it says the expiration was around 14 days back .).    Concomitant medication was not provided.  Treatment information was not provided.  This case contains information for the 1st patient out of 4 pediatric patients as described by the reporter.   This case was linked to US-MODERNATX, INC.-MOD-2023-712819, US-MODERNATX, INC.-MOD-2023-712821, US-MODERNATX, INC.-MOD-2023-712822 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-712819:Patient 2 US-MODERNATX, INC.-MOD-2023-712821:Patient 3 US-MODERNATX, INC.-MOD-2023-712822:Patient 4
Age: 65.0
Sex: F
Vaccine: COVID19-2
Symptoms: Expired product administered, No adverse event, Product storage error
Clinical narrative: This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Dose administered after 30-day Use By Date), PRODUCT STORAGE ERROR (The vial was initially stored in the refrigerator on 29-Dec-2022 and was administered on 02-Feb-2023) and NO ADVERSE EVENT (no adverse event) in a 65-year-old female patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. AS7172B) for COVID-19 prophylaxis. No Medical History information was reported.No concomitant information was reported.  Dosage text of the suspect was reported as unknown. It was reported that 7 doses were administered and the size of the vial was 2.5ml. Vaccine was administered to 2 patients on 31-Jan-2023, 2 patients on 02-Feb-2023 and 3 patients on 10-Feb-2023. The vial did not underwent any temperature excursion and the BUD date was 28-Jan-2023.  No treatment information was provided.
Age: 81.0
Sex: M
Vaccine: COVID19-2
Symptoms: Expired product administered, No adverse event, Product storage error
Clinical narrative: This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Dose administered after 30-day Use By Date / Date the vial was initially stored in the refrigerator: 29Dec2022/BUD: 28Jan2023), PRODUCT STORAGE ERROR (Vial was initially stored on 29-Dec-2022, BUD: 28-Jan-2023, drug administered on 02-Feb-2023) and NO ADVERSE EVENT (No adverse event) in an 81-year-old male patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. AS7172B) for COVID-19 prophylaxis.     No Medical History information was reported.
Age: 54.0
Sex: F
Vaccine: COVID19-2
Symptoms: Expired product administered, No adverse event, Product storage error
Clinical narrative: This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Dose administered after 30-day Use By Date), PRODUCT STORAGE ERROR (Dose administered after 30-day Use By Date) and NO ADVERSE EVENT (no adverse event) in a 54-year-old female patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. AS7172B) for COVID-19 prophylaxis.     Concurrent medical conditions included Immunocompromised.   For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (no adverse event) to be not related. No further causality assessments were provided for EXPIRED PRODUCT ADMINISTERED (Dose administered after 30-day Use By Date) and PRODUCT STORAGE ERROR (Dose administered after 30-day Use By Date).    No concomitant medications were reported.  The vial was initially stored in the refrigerator on 29-Dec-2022  The vial did not undergo any temperature excursions.  BUD was reported as 28-Jan-2023.  No treatment medications were reported.
Age: 73.0
Sex: F
Vaccine: COVID19-2
Symptoms: Expired product administered, No adverse event, Product storage error
Clinical narrative: This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Dose administered after 30-day Use By Date and BUD date was 28-Jan-2023), PRODUCT STORAGE ERROR (The vial was initially stored in the refrigerator on 29-Dec-2022 and was administered on 31-JAN-2023) and NO ADVERSE EVENT (no adverse event) in a 73-year-old female patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. AS7172B) for COVID-19 prophylaxis.     No Medical History information was reported.
Age: 94.0
Sex: F
Vaccine: COVID19-2
Symptoms: Expired product administered, No adverse event, Product storage error
Clinical narrative: This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Dose administered after 30-day Use By Date and BUD date was 28-Jan-2023), PRODUCT STORAGE ERROR (The vial was initially stored in the refrigerator on 29-Dec-2022 and was administered on 10-Feb-2023) and NO ADVERSE EVENT (No adverse event) in a 94-year-old female patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. AS7172B) for COVID-19 prophylaxis.     No Medical History information was reported.       No concomitant information was reported.
Age: 64.0
Sex: M
Vaccine: COVID19-2
Symptoms: No adverse event, Wrong product administered
Clinical narrative: This spontaneous case was reported by a pharmacist and describes the occurrence of WRONG PRODUCT ADMINISTERED (Patient received the 2nd dose of Moderna COVID-19 vaccine from a bivalent vial instead of Monovalent) and NO ADVERSE EVENT (No adverse event) in a 64-year-old male patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 prophylaxis.     No Medical History information was reported.     No concomitant medications were provided. The patient received first Primary monovalent dose on 26-Dec-2022 with unknown batch number. It was reported that the other pharmacist whom administered the vaccine on 27-Jan-2023, told the patient to come back in 1 month and receive the 2nd dose.  No treatment medication was provided.
Sex: U
Vaccine: COVID19-2
Symptoms: No adverse event, Wrong product administered
Clinical narrative: No adverse event; Patient received bivalent Moderna COVID19 vaccine as a first dose; This spontaneous case was reported by a pharmacist and describes the occurrence of WRONG PRODUCT ADMINISTERED (Patient received bivalent Moderna COVID19 vaccine as a first dose) and NO ADVERSE EVENT (No adverse event) in an adult patient of an unknown gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 011h22a) for COVID-19 prophylaxis.     No Medical History information was reported.    On 27-Jan-2023, the patient received first dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 27-Jan-2023,  after starting mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)), the patient experienced WRONG PRODUCT ADMINISTERED (Patient received bivalent Moderna COVID19 vaccine as a first dose). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, WRONG PRODUCT ADMINISTERED (Patient received bivalent Moderna COVID19 vaccine as a first dose) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for WRONG PRODUCT ADMINISTERED (Patient received bivalent Moderna COVID19 vaccine as a first dose).    It was unknown if the patient received any other vaccines in 4 weeks prior to COVID-19 vaccine.  No concomitant medications was reported. Patient received only one dose.  No treatment medications was reported.   Reporter did not allow further contact
Sex: U
Vaccine: PNC20
Symptoms: Syringe issue
Clinical narrative: syringe was broken; This is a spontaneous report received from contactable reporter(s) (Other HCP).  A patient (no qualifiers provided) received pneumococcal 20-val conj vac (dipht CRM197 protein) (PREVNAR 20), as dose number unknown, 0.5 ml single (Lot number: GM9409, Expiration Date: Aug2024) for immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: SYRINGE ISSUE (non-serious), outcome "unknown", described as "syringe was broken".  Additional information: NDC number of Prevnar 20: 0005200010. Product damaged in transit: Had it in the fridge, went to administer it and when it was taken out of the box it was realized that the neck of the syringe was broken and there was no vaccine in it. Order was received on 08Feb2023. Neck of the syringe was broken and there was no vaccine in it. First time product was ever damaged during transit, only one effected. Sample of the product available to be returned, if requested.
Sex: M
Vaccine: COVID19
Symptoms: Discomfort, Neck pain
Clinical narrative: after the vaccine he has felt uncomfortable; neck pain; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP) from medical information team, Program ID: (RA). The reporter is the patient.  A 70-year-old male patient received BNT162b2 (BNT162B2), on 13Jul2022 as dose 4 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history was not reported. Concomitant medication(s) included: ASPIRIN [ACETYLSALICYLIC ACID]. Vaccination history included: Bnt162b2 (Dose: 1), for Covid-19 immunization; Bnt162b2 (Dose: 2), for Covid-19 immunization; Bnt162b2 (Dose: 3 (booster)), for Covid-19 immunization. The following information was reported: DISCOMFORT (non-serious), outcome "unknown", described as "after the vaccine he has felt uncomfortable"; NECK PAIN (non-serious), outcome "recovered".  Additional information: It was reported that the patient had the primary series and two booster shots of the Pfizer BioNTech COVID-19 vaccine. He was planning on getting a third booster shot today but took Tylenol two days ago. Asked if its ok to take the booster shot even if he had the Tylenol. The patient had his last Pfizer COVID-19 booster shot on 13Jul2022 and getting surgery on early August. He also usually took 81mg Aspirin. Referred that after the vaccine he felt uncomfortable and with neck pain for about a day and a half "but nothing serious" Caller was asking if that inhibits him going today and getting his next shot.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Sex: U
Vaccine: COVID19
Symptoms: Drug ineffective, Suspected COVID-19
Clinical narrative: we both had breakthrough covid cases; we both had breakthrough covid cases; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team.  A patient (no qualifiers provided) received BNT162b2 (BNT162B2), as dose 1, single (Batch/Lot number: unknown) and as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), SUSPECTED COVID-19 (medically significant), outcome "unknown" and all described as "we both had breakthrough covid cases".  Clinical course: Caller provided case number 00886945 and confirmed inquiry in that original and linked interaction. He confirms that he got the Pfizer covid vaccine for his first two doses to complete the primary series and shares his experience "The pain is sort of like a dull pain and it started a couple of weeks after the vaccinations its been continuing on since then and it hasnt gone away which is rather disturbing. I've had a flu vaccine whcih was heavy, I had a sore arm for about week and then it went away. After we (presumably he and his wife) discovered what was going on with the vaccines we both decided to go against it, both of us caught at the same time we both had breakthrough covid cases we weren't pleased with the results of this vaccine. I have no HCP, I had vertigo and the guy treated me like I was a hypochondriac, they threw all of this "" at me which costs money and did nothing. They got me to do the apline maneuver, its little crystals in your ears its horrible but its little crystals in your ear canals they start to form and then it falls and it all your hairs in you ears and it make you feel just like your'e spinning". According to the agent who handled the call: "I went and relistened to the conversation I had with him because I was afraid to miss some AEs and I noticed that he was actually reporting about two persons. Now because I relistened to the call I wasn't able to confirm who the other person the caller was reporting for." Thus, reporter was reporting on himself and another person but may not have specifically been his wife. It was an assumption.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202300080002 Same reporter/drug/event for different patients.;
Age: 30.0
Sex: M
Vaccine: COVID19
Symptoms: Head discomfort, Headache, Ocular discomfort, SARS-CoV-2 test
Clinical narrative: Since getting the vaccine I've been dealing with headaches; and pressure that moves around my head and eyes; and pressure that moves around my head and eyes; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 30-year-old male patient received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 09Jan2023 at 14:00 as dose 4 (booster), single (Batch/Lot number: unknown) at the age of 30 years, in left arm for covid-19 immunisation. The patient's relevant medical history was not reported. There were no concomitant medications. Vaccination history included: Covid-19 vaccine (Dose: 1, MANUFACTURER UNKNOWN), for Covid-19 immunization; Covid-19 vaccine (Dose: 2, MANUFACTURER UNKNOWN), for Covid-19 immunization; Covid-19 vaccine (Dose: 3, MANUFACTURER UNKNOWN), for Covid-19 immunization. The following information was reported: HEADACHE (non-serious) with onset 16Jan2023, outcome "not recovered", described as "Since getting the vaccine I've been dealing with headaches"; HEAD DISCOMFORT (non-serious), OCULAR DISCOMFORT (non-serious) all with onset 16Jan2023, outcome "not recovered" and all described as "and pressure that moves around my head and eyes". The events "since getting the vaccine i've been dealing with headaches" and "and pressure that moves around my head and eyes" required physician office visit and emergency room visit. Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were taken as a result of headache, head discomfort, ocular discomfort.  Additional Information: There was no other vaccine in four weeks and no other medications in two weeks. Since getting the vaccine I've been dealing with headaches and pressure that moves around my head and eyes on 16Jan2023. The events received treatment of Magnesium. It was reported that no covid prior vaccination and covid tested post vaccination.   The information on the batch/lot number for [BNT162B2, BNT162B2 OMI BA.4-5] has been requested and will be submitted if and when received.
Sex: F
Vaccine: COVID19
Symptoms: Chills, Pyrexia
Clinical narrative: Chills; Fever; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the patient.  A female patient received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), as dose 4 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (DOSE 1, SINGLE, Manufacturer Unknown), for COVID-19 immunization; Covid-19 vaccine (DOSE 2, SINGLE, Manufacturer Unknown), for COVID-19 immunization; Covid-19 vaccine (DOSE 3 (BOOSTER), SINGLE, Manufacturer Unknown), for COVID-19 immunization. The following information was reported: CHILLS (non-serious), outcome "unknown"; PYREXIA (non-serious), outcome "recovering", described as "Fever".  Additional information: Temperature was going down already and she was much better.  The information on the batch/lot number for BNT162b2, BNT162b2 omi ba.4-5 has been requested and will be submitted if and when received.
Age: 91.0
Sex: U
Vaccine: UNK
Symptoms: COVID-19
Clinical narrative: Got Covid, was vax'd
Age: 78.0
Sex: M
Vaccine: UNK
Symptoms: COVID-19, SARS-CoV-2 test positive
Clinical narrative: Covid + and was vaccinated
Age: 54.0
Sex: F
Vaccine: COVID19-2
Symptoms: COVID-19, SARS-CoV-2 test positive, Vaccine breakthrough infection
Clinical narrative: covid vaccine breakthrough case  All Moderna dose 1 3/17/21  007B21A dose 2 4/14/21  043B21A dose 3 11/26/21 067F (lot number incorrect, but do not have access to correct number)
Age: 69.0
Sex: M
Vaccine: TDAP, VARZOS
Symptoms: Pruritus
Clinical narrative: Patient reported feeling itchy
Age: 26.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: no adverse  effects reported.   vial used was opened 1/30/23 and not disposed of.
Age: 35.0
Sex: F
Vaccine: TDAP
Symptoms: Injection site discharge, No adverse event, Underdose
Clinical narrative: Nurse was giving injection per normal fashion. After she depressed the plunger and took the needle out of the patient arm part the immunization came out . It is unknown how  much. Nurse did note that after pulling the needle out it was  not tight to the syringe. Again unsure the amount of the 0.5ml dose the patient received. No adverse reaction just unclear the dose given and the next step. Should she be given another dose ? Looking for direction.
Age: 61.0
Sex: F
Vaccine: COVID19-2
Symptoms: Medication error, Product storage error
Clinical narrative: Medication error. Vaccine not viable due to improper storage.
Age: 56.0
Sex: M
Vaccine: COVID19-2
Symptoms: Anticoagulant therapy, Aphasia, Atrial septal defect, Contrast echocardiogram, Embolic stroke
Clinical narrative: On January 11th, I woke up in the middle of the night and felt strange sensations in my face. Had trouble speaking and had right side face droop. Next day went to heath care provider. I was given an exam. Vitals were all within range.  PA gave me baby aspirin and suggested a hospital visit. I checked into hospital and got an MRI and CAT scan. MRI showed I had had recent embolic stroke activity. Tests showed I had a Patent Foramen Oval, which was previously unknown. My test showed good health otherwise. Doctors treated me with Lipitor Plavix and baby aspirin. I?ve had no symptoms since.
Age: 56.0
Sex: M
Vaccine: COVID19-2
Symptoms: Facial paralysis, Magnetic resonance imaging head abnormal, Middle insomnia, Sensory disturbance
Clinical narrative: On January 11th, I woke up in the middle of the night and felt strange sensations in my face. Had trouble speaking and had right side face droop. Next day went to heath care provider. I was given an exam. Vitals were all within range.  PA gave me baby aspirin and suggested a hospital visit. I checked into hospital and got an MRI and CAT scan. MRI showed I had had recent embolic stroke activity. Tests showed I had a Patent Foramen Oval, which was previously unknown. My test showed good health otherwise. Doctors treated me with Lipitor Plavix and baby aspirin. I?ve had no symptoms since.
Age: 51.0
Sex: M
Vaccine: COVID19-2
Symptoms: Medication error, Product storage error
Clinical narrative: Medication error. Vaccine not viable due to improper storage.
Age: 54.0
Sex: F
Vaccine: COVID19
Symptoms: Pruritus, Rash, Rash erythematous
Clinical narrative: I experienced itching around my neck that progressed into a red rash that spread to my shoulders and legs.
Age: 56.0
Sex: F
Vaccine: COVID19-2, PNC20
Symptoms: Medication error, Product storage error
Clinical narrative: Medication error. Covid booster not viable due to improper storage.
Age: 70.0
Sex: M
Vaccine: COVID19-2, FLU4
Symptoms: Medication error, Product storage error
Clinical narrative: Medication error. Covid booster not viable due to improper storage.